Trillium™
Ratio ’s Trillium™ technology is a proprietary and innovative platform
that incorporates a tunable, structural motif enabling our compounds to
reversibly bind to albumin, thereby modulating their pharmacokinetics (PK)
and improving drug availability, tumor delivery, and tumor loading,
while simultaneously reducing the side effects commonly observed with
other radiotherapies.